Oncolens, an Atlanta, GA-based oncology health tech startup, raised $16m in Series A funding.
The round was co-led by BIP Capital and Cross Border Impact Ventures with participaiton from Martin Ventures and SeedToB.
The company intends to use the funds to expand its development efforts.
Led by Anju Mathew, CEO, OncoLens is a leader in optimizing cancer treatment planning serving national cancer institutes (NCIs), academic medical centers and community based integrated delivery networks (IDNs). Its proprietary oncology focused AI capabilities provide cancer centers the ability to extract key insights from structured or unstructured clinical, molecular and other lab data to find patients who might have missed treatment-defining diagnostics or therapies, in real time. OncoLens’ collaboration solutions can then be used to coordinate next steps on those patients to ensure action is taken in a timely and multidisciplinary manner.
OncoLens serves care providers internationally as well, having launched in the EMEA (Europe, Middle East and Africa) region in 2022. With the growth of its customer base, the company launched the OncoLens Research Network, partnering closely with life science commercial, real world evidence and clinical development teams to bring cutting edge research including trials and quality improvement initiatives to their centers. For life science partners, OncoLens brings a diverse, community focused network of centers to address real world evidence, diversity and inclusion in trials or finding patients with extremely rare genomic alterations or conditions.
FinSMEs
24/10/2024